CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 12, 2006--Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, announced that it will present preclinical data highlighting the anabolic bone activity of ACE-011, the company's lead drug candidate and a novel treatment for bone loss, at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR).
